Roche preps new Kadcyla filings after phase 3 trial win

evidence that giving it in place of Herceptin would actually make patients less likely to relapse. ... That will help support the $10bn-plus franchise as Herceptin faces the threat of biosimilar competition in some European markets, including the UK.

Ocrevus surge keeps Roche smiling in Q3

As expected, biosimilar competition to two of its top products – MabThera and Herceptin – weighed heavy on Roche in the third quarter in Europe. ... Meanwhile, breast cancer therapy Herceptin (trastuzumab) also continued its European decline thanks

Encouraging data for Roche flu drug ahead of FDA decision

Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

in HER2 positive, unresectable and/or metastatic breast cancer previously treated with Roche’s Herceptin (trastuzumab) and taxane chemotherapy. ... Despite a couple of knockbacks in trials seeking to expand its uses into other indications such as

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]